圣达生物 (603079.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.8x

Market Cap

CNY 2.39B

MomentumView details →

1D Return

−9.98%

YTD Return

−27.31%

RSI (14)

50.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.8x

Market Cap

CNY 2.39B

RSI (14)

50.5

MomentumView details →

1D Return

−9.98%

YTD Return

−27.31%

ProfitabilityView details →

Gross Margin

25.81%

Net Margin

6.46%

EBITDA Margin

19.46%

ROE (TTM)

3.36%

ROA (TTM)

2.45%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

−1.81%

EPS YoY

+6.35%

FCF YoY

+149.75%

Revenue CAGR 3Y

+4.60%

EPS CAGR 3Y

+24.81%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

4.69x

Quick Ratio

3.64x

Div Yield

0.78%

Div Rate

CNY 0.10

Div Growth 1Y

+66.67%

Financials snapshotView financials →

Revenue (TTM)

830.53M

Net Income (TTM)

53.62M

Op. CF (TTM)

156.78M

Latest newsMore news →

Shengda Bio appointed Lin Weiyuan as board secretary and Mi Yexuan as securities affairs representative on July 6, 2026.60d ago

Similar companies

Hua Medicine (Shanghai) Ltd.02552.HK Bausch Health Companies Inc.BHC HUTCHMED (China) LimitedHCM Supernus Pharmaceuticals, Inc.SUPN Chia Tai Enterprises International Limited03839.HK Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.01349.HK Find similar companies →

Latest newsMore news →

Shengda Bio appointed Lin Weiyuan as board secretary and Mi Yexuan as securities affairs representative on July 6, 2026.60d ago